Replies to post #248445 on Biotech Values

[mouton29]

…I don't think ABT will be strongly affected by the uptake of weight-loss drugs. ABT is not a player in the hip- and knee-implant market, ZBH's main business, where obesity clearly plays a major role. Meanwhile, ABT is strong beneficiary of the increasing wolrdwide prevalence of T2D

Obesity is also a risk factor for T2D, but I’m not convinced weight loss drugs will be enough to tip the scales against that trend.